MIRI, SYNA
MIRI, SYNA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Mostra
records
Risultati 1 - 4 di 4 (tempo di esecuzione: 0.0 secondi).
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
2024 J.A. Giannotta, A. Artoni, I. Mancini, P. Agosti, M. Carpenedo, A. Truma, S. Miri, B. Ferrari, P. De Leo, P. Salutari, G. Mancini, A. Molteni, E. Rinaldi, M. Bocchia, M. Napolitano, L. Prezioso, A. Cuccaro, E. Scarpa, A. Condorelli, D. Grimaldi, M. Massaia, F. Peyvandi
PHD / DOTTORATO
2023 S. Miri
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
2021 F. Peyvandi, S. Miri, I. Garagiola
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
2020 F. Peyvandi, S. Miri, P. Bucciarelli, C. Valsecchi, L. Schiavone, M. Boscarino, R. Palla, P.M. Mannucci, F.R. Rosendaal
| Titolo | Data di pubblicazione | Autori | Tipo | File | Abstract |
|---|---|---|---|---|---|
| Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study | 2024 | Giannotta, Juri AlessandroMancini, IlariaAgosti, PasqualeTruma, AddolorataMiri, SynaPeyvandi, Flora + | Article (author) | - | |
| PHD / DOTTORATO | 2023 | MIRI, SYNA | Doctoral Thesis | - | |
| Immune Responses to Plasma-Derived Versus Recombinant FVIII Products | 2021 | Peyvandi F.Miri S.Garagiola I. | Article (author) | - | |
| IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A | 2020 | Peyvandi F.Miri S.Bucciarelli P.Valsecchi C.Palla R.Mannucci P. M. + | Article (author) | - |